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In severa l intestinal disease states, altered micro ora, impaired gut barrier and:or intestinal in ammation offer a rationale for the effective
therapeut ic use of probiotic microorganisms. However , for most candidate probiotic organisms there is a lack of evidence detailing their
characterisation and effects on host  ora and immunity. We have previously reported the isolation and characterisation, from surgically
resected segment s of the human gastrointestinal tract (GIT), of potential probiotic lactic acid bacteria (LAB). We have also described
subsequen t animal experiments that evaluated the establishment , persistence and localisation of speci c probiotic Lactobacillus strains
within the murine intestinal tract, in addition to their ability to in uence the developmen t of murine in ammatory disorders. In these
studies, transit and surviva l of Lactobacillus salivarius UCC118 at the ileum was demonstrated using enteral tube sampling of six healthy
volunteer s following consumption of a single dose (150 ml) of fermented milk-borne probiotic (108 colony forming units per ml
(CFU :ml)). Subsequently, we performed a randomised controlled trial of 80 volunteer s fed strain UCC118 (108 CFU:day for 21 d), using
two oral delivery vehicles (fresh milk, n¾20 vs. fermented milk, n¾20; controls, n¾20 for each). Throughout this feeding period, and
for up to 100 days following cessation of feeding, the numbers of total culturable lactobacilli and of the administered Lactobacillus
UCC118 present in faeces were monitored. F ive subjects (5:40; fresh milk, four; fermented milk, one) were still excreting the probiotic
lactobacilli 21 days post-cessation of feeding, while one subject (fermented milk) was still colonised up to 100 days after feeding.
Consumpt ion of fermented milk-borne UCC118 cells resulted in signi cantly increased levels of faecal-borne enterococci and lactobacilli.
Numbers of bi dobacteria, coliforms and bacteroides were not signi cantly altered. In addition, changes in salivary IgA levels against
UCC118 cells and increased granulocyt e phagocytic activity were observed following consumption of the fermented milk-borne probiotic.
In summary, Lactobacillus UCC118 was found to effectively transit (and persist within) the human intestinal tract, to modify the faecal
 ora and to engage the immune system. Key words : controlled trial, probiotic, Lactobacillus salivarius, transit,  ora, enteric immunity.
ORIGINAL ARTICLE
INTRODUCTION
The intestinal micro ora is characterised by its density,
diversity and complexity of interactions and is both an
asset and a potential liability in health and disease, de-
pending on genetic and other host susceptibility factors
(1). There are up to 10-fold more bacteria in the human
gut than cells in the body and this accounts for about 1–2
kg of intestinal contents composed of an estimated 50
genera, belonging to over 400 separate species (2). With a
metabolic activity rivalling that of the liver (3, 4), the
gastrointestinal micro ora has been described as a
metabolically adaptable and rapidly renewable organ of
the body, the composition and activities of which can
affect both intestinal and systemic physiology (5, 6). The
 ora represents a central component of mucosal defence,
has a priming effect on mucosal immune function, and has
a conditioning effect on mucosal structure and function
(7–10). This is strikingly evident in germ-free animals that
exhibit reductions in epithelial turnover, motility, smooth
muscle function, vascularity and gut-associated lymphoid
tissue (11). Alterations in bacterial  ora are associated
with susceptibility to pathogens such as Clostridium dif -
cile and there is persuasive evidence that the normal  ora
may participate in the pathogenesis of in ammatory bowel
disease in genetically susceptible individuals (12–14). This
has prompted various strategies to fortify or otherwise
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modify the enteric  ora using dietary supplements. Al-
though the theoretical rationale for modifying the enteric
 ora in speci c circumstances appears sound and requires
scienti c pursuit, the  eld has been clouded by wildly
exaggerated claims from some quarters. Simplistic notions
of ‘bowel cleansing’ are conceptually appealing as por-
trayed in the popular lay press; have been exploited com-
mercially, often without impressive evidence for ef cacy;
and have been adopted by some enthusiasts of alternative
medicine. However, the use of biotherapeutic agents such
as probiotics has recently attracted scienti c input from
disparate traditional disciplines, including microbiology
and gastroenterology (14).
Probiotics are live microbial food ingredients (or phar-
maceutical-type preparations) that alter the enteric mi-
cro ora and have a bene cial effect on health (12, 14, 15).
Probiotic research promises much, and ambitious claims
have been made for their potential contribution to health
maintenance and treatment of disease. At present, how-
ever, many of the purported bene ts have not yet been
matched with persuasive supporting evidence (16).
To overcome the scepticism of some members of the
scienti c community regarding probiotic products, their
safety and their associated probiotic claims (17), the char-
acterisation and assessment of candidate probiotic organ-
isms must be rigorous. However, to-date, detailed
comparisons of probiotic performance amongst different
strains have not been performed in vivo in healthy humans
or under clinical trial conditions and the level of scienti c
characterisation of individual probiotic organisms has
been variable. Furthermore, the heterogeneity of clinical
disorders such as Crohn’s disease and ulcerative colitis
implies that it is unlikely that any single probiotic will be
equally suitable for all individuals and that strain-speci c
properties may be required for subset-speci c categories of
patients (12).
In previous reports, we and others have described strate-
gies adopted speci cally to comply with criteria recom-
mended (18, 19) for the selection of potential probiotic
microbes for use in humans. These approaches resulted in
the isolation of Lactobacillus strains from healthy human
adults (20, 21) and their subsequent assessment in murine
models (22). In this study, our objective was to further
characterise the probiotic Lactobacillus salivarius strain
UCC118 and to focus speci cally upon: (i) effective deliv-
ery of the probiotic micro-organism to the human gut
using fermented and non-fermented delivery vehicles; (ii)
evaluation of the ability of the strain to survive transit
through (and persist within) the human intestinal tract;
(iii) accepting the complexity of the hostile intestinal and
faecal environments, assessment of a method of enumerat-
ing the introduced bacterial strain using conventional mi-
crobiological techniques; (iv) determining the effect of
probiotic consumption on the numbers of faecal-borne
selected indigenous bacteria; and (v) evaluation of immune
recognition of the consumed probiotic bacteria.
MATERIALS AND METHODS
Production of probiotic test products
Fermented milk (yoghurt-like) and fresh milk products
containing the L. salivarius UCC118 strain were prepared
to Good Manufacturing Practice (GMP) standards. Fer-
mented milk production involved inoculating pasteurised
cows’ milk with a spontaneous rifampicin-resistant deriva-
tive (22) of L. salivarius UCC118 (L. salivarius UCC118Rif)
and a commercial strain of Streptococcus thermophilus.
Prior to inoculation into milk, the Lactobacillus strain was
grown in liquid deMann, Rogosa & Sharpe (MRS)
medium (Oxoid, UK) overnight at 37°C, centrifuged, and
washed twice in sterile PBS. The inoculated milk was
incubated at 37°C until Lactobacillus numbers reached 108
colony-forming units per g (CFU :g). F resh milk test
product was produced by adding L. salivarius UCC118Rif,
following incubation and washing as described above, to
achieve numbers of 108 CFU :ml. The control fermented
milk product was inoculated with S. thermophilus alone
while the control fresh milk product was untreated beyond
the typical pasteurisation process.
Human intestinal transit and survival of L. salivarius
UCC118Rif
To establish kinetics and transit of the L. salivarius
UCC118Rif strain at the human ileum sampling from the
human ileum was performed after single dose feeding using
an enteral tube. This aspect of the study was approved by
the Ethics Committee at Hopital St. Lazare, Paris, F rance,
and was conducted at the same location. Six healthy
human volunteers consented to intestinal intubation with a
triple-lumen tube, after an overnight fast, as previously
described (23). This permitted sampling of ileal contents 35
cm above the ileo-cecal junction. Equilibration was accom-
plished by infusing 10 g polyethylene glycol (PEG) 4000 in
154 mM NaCl at 37°C at a rate of 2 ml:min. After 1 h of
equilibration, each subject ingested a standard meal of 150
ml fermented milk containing L. salivarius UCC118Rif (108
CFU :ml). Before feeding, 108 bacterial spores of Bacillus
stearothermophilus (Merck, Darmstadt, FRG), which ger-
minate only at 65°C, were added to the fermented milk as
a bacterial marker (23). Ileal content was continuously
collected on ice by manual aspiration for 8 h after fer-
mented milk consumption. Another standard meal was
then ingested and two further 5 ml samples of ileal  uid
collected 10 and 24 h after fermented milk consumption.
The ileal  uid samples were pooled into 1 h aliquots and
microbial counts were performed immediately at the end
of each hour of collection. The samples were serially
diluted 10-fold in sterile phosphate-buffered saline (PBS)
and 0.1 ml of each dilution spread-plated onto freshly
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prepared media. The medium used was MRS agar-con-
taining rifampicin (50 mg:ml). Plates were incubated in
anaerobic jars using CO2-generating kits (Anaerocult A;
Merck) for 2 days at 37°C. Spores of B. stearothermophilus
were quanti ed on plate count agar (PCA; Bio-Merieux,
Craponne, F rance) after  rstly incubating aerobically at
65°C for 24 h.
Double -blind placebo-controlled feeding trial
A randomised double-blind, placebo-controlled feeding
trial was undertaken to compare two oral delivery vehicles
(fresh and fermented milk) for UCC118Rif and to assess
the in uence of the probiotic Lactobacillus strain on the
faecal microbial  ora and health status of consumers. The
trial was conducted at National University of Ireland,
Cork. Eighty healthy human volunteers (29 male, 51 fe-
male) aged from 20 to 65 years were recruited on the basis
of no recent history of antibiotic therapy, no chronic
in ammatory or viral illness, no current drug therapy, no
known allergies, no participation in other clinical trials. In
addition, candidates for the trial were excluded if pregnant
or if suffering from IgA de ciency. All subjects gave
written informed consent and the study protocol was
approved by the Cork University Hospitals Ethics Com-
mittee. The duration of the study was 9 weeks (Fig. 1).
During this period, all volunteers were requested to ex-
clude fermented dairy products from their diet. Week 1–3
acted as a stabilisation period. Consumption of test
product occurred from week 4–6. During week 7–9, trial
products were again removed from the diet. Prior to
commencement of the study, volunteers were randomly
assigned to one of four groups (A, B, C, D; n¾20 each).
Group A were fed pasteurised milk (120 ml:day) contain-
ing UCC118Rif (108 CFU :ml; i.e. 1010 CFU :day); group B
were fed control pasteurised milk (120 ml:day); group C
were fed fermented milk (120 g:day) containing UCC118
Rif (108 CFU :ml; i.e. 1010 CFU :day); group D were fed
control fermented milk (120 g:day). On the  rst day of
feeding (T0), the day after the feeding period (T1) and 21
days after termination of feeding (T2), samples of faeces,
blood and saliva were collected. During the feeding period
two volunteers (both from consumer group D) voluntarily
withdrew from the study.
Analysis of faecal micro ora
Microbial analysis was performed on faecal samples within
6 h of collection. Each sample was weighed and resus-
pended in 10 ml of sterile PBS. The samples were serially
diluted 10-fold in sterile PBS and either pour-plated or
spread-plated in appropriate dilutions on suitable media,
and incubated in anaerobic jars (BBL) using CO2-generat-
ing kits (Anaerocult A; Merck) for 2–5 days at 37°C. The
selective media employed for the culture of lactobacilli,
bi dobacteria, enterococci, bacteroides and coliforms, re-
spectively were as follows: deMann, Rogosa & Sharpe
(MRS) agar, Trypticase:Peptone:Yeast extract (TPY)
agar, Slanetz & Bartley agar, Wilkins & Chalgren agar and
Violet Red Bile agar (VRBA), respectively (all Oxoid,
UK). MRS supplemented with rifampicin (50 mg:ml) was
used for the selective culture of L. salivarius UCC118Rif.
Microbial numbers were calculated as CFU :g of wet
weight faeces.
Salivary and serum antibodies speci c for L. salivarius
UCC118Rif
Salivary IgA speci c for the probiotic lactobacilli was
quanti ed by  ow cytometry as follows. Saliva samples
were stored at ¼80°C to reduce viscosity, and concentra-
tion was standardised based on total protein concentration
in each sample. A fresh overnight culture of L. salivarius
UCC118Rif was washed and resuspended in PBS at a
concentration of 108 cells:ml. One hundred microlitres of
bacterial suspension was mixed with 100 m l saliva (1:10–
1:100 in PBS) and incubated for 1 h at room temperature.
The bacterial cells were then centrifuged and washed in
PBS, resuspended in 100 m l F ITC-labelled a chain-speci c
rabbit anti-human IgA monoclonal antibody (1:40 diluted)
(DAKOPATTS, Denmark) and incubated for 30 min at
room temperature. The cells were washed again in PBS
and resuspended in 200 m l isotonic carrier  uid (Isoton 2;
Coulter, Luton, UK). The  uorescence of the cells was
then measured by  ow cytometry using a Coulter ‘Epics
Elite’ F luorescence-Activated Cell Sorter (FACS) (Coulter,
Luton, UK). Mean  uorescence intensity was recorded
and standardised against salivary protein concentration.
Standard curves were constructed and mean  uorescence
Fig. 1. Protocol design for a feeding
trial assessing the delivery and pro-
biotic ef cacy of L. salivarius
UCC118Rif in human volunteers.
Key: T0¾starting day of feeding,
T1¾day after termination of feeding,
T2¾21 days after termination of
feeding; F¾faecal sample, B¾blood
sample, S¾ saliva sample.
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index (MFI) was directly proportional to salivary concen-
tration in a linear fashion. A positive antibody response
was interpreted as a ]75% increase in the MFI.
F low cytometry was similarly employed to measure
serum IgG speci c for UCC118Rif lactobacilli. The proto-
col was identical to that used in salivary detection; each
serum sample was diluted 1 in 10 in PBS and FITC-la-
belled goat g-chain speci c anti-human IgG monoclonal
antibody (1:32) (Sigma:Aldrich Chemical Co., Dorset,
UK) was employed as the secondary antibody.
Serum immunoglobuli n and cytokine measurements
The overall immune status of participating volunteers was
monitored by measuring the following parameters. Total
serum IgG, total serum IgM and total serum IgA were
assessed by immunoturbidometric assay (Tina-quant;
Boehringer Mannheim, East Sussex, UK). Serum IgE lev-
els were quanti ed by ELISA. In ammatory cytokines, i.e.
interleukin-(IL)-1a, IL-1b, IL-4, soluble IL-2 receptor, sol-
uble IL-6 receptor, tumour necrosis factor-(TNF)-a, and
interferon-(IFN)-g, were quanti ed in serum employing
enzyme linked immunosorbent assay (ELISA) immunode-
tection (Quantikine; R & D Systems, Oxon, UK)
Peripheral leukocyte phagocytic activity
Leukocyte phagocytic activity in peripheral blood was
quanti ed by  ow cytometry employing  uoroscein isoth-
iocyanate (FITC)-labelled opsonised Escherichia coli
(PHAGOTEST; Becton Dickinson, Belgium). F resh hep-
arinized blood (100 m l) was mixed with 20 m l of an E. coli
suspension (1½109 bacteria per ml) so that that the ratio
of bacteria to leukocytes was approximately 20:1 (v:v).
The mixture was then incubated for 10 min at 37°C in a
water bath. After quenching, to eliminate bacteria not
ingested by leukocytes, the red blood cells in the sample
were lysed, and the remaining cells  xed and stained with
a propidium iodide solution. F luorescence measurements
were made  ow cytometrically with blue–green excitation
light (488 nm). Employing LYSIS II data analysis software
(Becton Dickinson), a live gate was set so that only events
that were positive for propidium iodide staining and,
hence, human diploid cells were considered. In analysis of
the data, the phagocytic activity of individual granulocyte
and monocyte populations, represented by internalised
bacterial  uorescence, were determined as expressed as a
percentage of total cells.
Statistical analysis
Comparisons of fresh and fermented milk delivery systems,
and L. salivarius UCC118Rif and placebo treatments, were
made by assessing all parameters for signi cant changes
between baseline (T0) and either T1 (3 weeks of probiotic
feeding) or T2 (3 weeks after cessation of probiotic feed-
ing). For the faecal microbial counts, primary statistical
analysis was performed on log-equality factors using
ANOVA. For UCC118Rif concentrations, the Wilcoxan
Rank Sum test was used. UCC118Rif -speci c serum anti-
body titers and serum cytokine levels were analysed by a
Wilcoxan two-sample test. UCC118Rif -speci c salivary
IgA levels were assessed by Fisher’s Exact Test (two-
tailed). All statistical analyses were devised and performed
by Independent Data Management Ltd., Cork, Ireland.
RESULTS
Transit :survival of L. salivarius UCC118Rif in the human
gut
In the six individuals who volunteered for preliminary
enteric intubation feeding analysis, L. salivarius UCC118Rif
was found to be delivered in signi cant numbers to the
terminal ileum and to have a strong capacity for survival.
Within 2 h of ingestion of fermented milk, signi cant
numbers of rifampicin-resistant lactobacilli (mean: \105
CFU :ml) were isolated in the ileal  uid of each subject
(Fig. 2). At 3 h after dose consumption, the  ow of
probiotic lactobacilli through the ileum was at its highest,
with the strain detectable at numbers of º2.0½106 CFU :
ml (Fig. 2). The survival capacity of the Lactobacillus
UCC118Rif strain until the terminal ileum, calculated as a
percentage of original number of bacteria consumed, was
approximately 11.8%. Viable UCC118Rif cells were still
detectable in the subjects at º105 CFU :ml for up to 7 h
after dose consumption. None of the strain persisted in the
lumenal content of the ileum after 8–10 h.
Human feeding trial of L. salivarius UCC118Rif
Of 80 subjects enrolled in the feeding trial, all except two
completed the study; none developed adverse effects and
no evidence of systemic in ammatory activity was de-
tected. UCC118Rif cells were delivered in high numbers to
the gastrointestinal tracts (GITs) of the study subjects by
both fresh milk and fermented milk products. Prior to the
feeding period, no bacteria were isolated from subject
faeces on MRS medium containing rifampicin. After feed-
ing, 39 of the 40 volunteers fed with UCC118Rif-containing
product (1010 CFU :day, for 21 days) exhibited signi cant
faecal excretion (103–107 CFU :g wet weight faeces) of
rifampicin resistant lactobacilli (F ig. 3). These bacteria
were con rmed to be L. salivarius UCC118Rif on the basis
of the ability to inhibit the growth of the B. coagulans 1761
indicator strain on solid media, as described previously
(22). This also con rmed general compliance with the
feeding regimen. As expected, excretion of L. salivarius
UCC118Rif was not detected in any of the control-fed
subjects. Based on faecal excretion levels, fresh milk was
found on average to deliver 15 times more UCC118Rif
Lactobacillus cells (F ig. 3; mean; 3.7½106 CFU:g faeces)
than fermented milk (Fig. 3; mean; 2.4½105 CFU :g fae-
ces). Of the volunteers fed test product (n¾40),  ve
individuals (12.5%) were found to have signi cant faecal
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Fig. 2. Transit and surviva l of L. salivarius
UCC118Rif to the ileum in healthy subjects
(n¾6). Fermented milk (150 ml) contain-
ing UCC118Rif (108 bacteria per ml) was
consumed , and  uid from the terminal
ileum collected by enteric sampling at
hourly intervals post-feeding. Mean con-
centrations (CFU:g) of UCC118Rif and a
marker bacterial strain B. stearother -
mophilus  owing at the terminal ileum at
various time-points after ingestion of fer-
mented milk are shown.
concentrations of the Lactobacillus UCC118Rif strain 21
days after termination of feeding (Fig. 3). Four of these
subjects were in the fresh milk delivery group, while the
other one was a fermented milk consumer. Hundred days
after the feeding period  nished, one individual in the
fermented milk delivery group was still excreting de-
tectable faecal levels of strain UCC118Rif (F ig. 3).
Modulation of faecal  ora in response to L. salivarius
UCC118Rif feeding
Faecal concentrations of total lactobacilli were also ele-
vated (mean 11.5-fold) compared with pre-feeding levels
(Fig. 4), in the group fed fermented milk containing the
UCC118Rif probiotic, and these reverted to baseline levels
when assessed 21 days post-feeding. In contrast, in subjects
fed fresh milk containing the UCC118Rif probiotic and in
both control groups, the change in faecal concentrations of
both enterococci and total lactobacilli was not statistically
signi cant. Faecal enterococci were elevated 200-fold in
subjects after 3 weeks of consumption of the Lactobacillus
UCC118Rif-fermented milk compared with baseline (Fig.
5). However, 3 weeks after cessation of feeding, the faecal
enterococci numbers, although still elevated, returned to-
ward baseline levels in almost all subjects. Additionally, no
signi cant change occurred in the faecal populations of
either bi dobacteria, bacteroides, coliforms as a result of
probiotic product ingestion (data not shown)
Engagement of the mucosal immune response by L.
salivarius UCC118Rif
Out of the 78 volunteers who completed the feeding trial
49 (63%) had detectable pre-existing serum IgG against the
L. salivarius UCC118Rif strain at baseline. After feeding,
there was no increase in the number of volunteers exhibit-
ing a UCC118Rif-speci c systemic serologic response, and
no elevation in the titer of UCC118Rif-speci c serum IgG
(agglutination index) amongst those who were serologi-
cally positive at baseline.
In contrast to the lack of systemic antibody response,
mean levels of mucosal (salivary) IgA against L. salivarius
UCC118Rif were elevated following consumption of the
probiotic (Table I). At week 3, the number of subjects with
positive shifts from baseline of \75% in salivary IgA
speci cally against UCC118Rif was signi cantly greater for
those receiving the probiotic either by fermented milk or
milk than for the controls (12:40 vs. 2:38; pB0.01). Dif-
ferences at week 6 were similarly signi cant (12:40 vs.
2:38; pB0.01). When analysed by sub-groups, at week 3
post feeding, the number of subjects with positive shifts
from baseline of \75% in salivary UCC118Rif -speci c
IgA concentrations was signi cantly different for those
who received the probiotic via fermented milk compared
with control fermented product (7:20 vs. 0:18; p¾0.009).
The difference in the proportions of positive shifts between
the two groups, at week 6, i.e. 3 weeks following cessation
of probiotic consumption, was also signi cant (6:20 vs.
0:18; p¾0.021). Although a greater proportion of those
consuming milk containing UCC118 Rif had a \75% shift
in UCC118 Rif-speci c IgA (5:20 vs 2:18), the difference
was not statistically signi cant at week 3 or 6.
Systemic immune parameters and phagocytic activity in
response to L. salivarius UCC118Rif
No systemic immune or in ammatory activity was found
in association with probiotic consumption. There was no
signi cant difference in change from baseline serum con-
centration for subjects receiving probiotic UCC118Rif via
fermented milk or fresh milk versus respective controls at
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Fig. 3. Faecal excretion of L. salivarius UCC118Rif by human
volunteers. L. salivarius UCC118Rif numbers isolated from faeces
(CFU :g wet weight) before (T0), immediately after (T1) and 21
days after (T2) consumption of test product are indicated for each
subject . Faecal L. salivarius UCC118Rif numbers at 100 days after
cessation of product consumption (T3) are indicated for those  ve
volunteer s who exhibited persistent L. salivarius UCC118Rif at T2.
DISCUSSION
The concept of health promotion through the ingestion of
functional foods, including those that act as vehicles for
potentially bene cial micro-organisms, has received con-
siderable attention (15, 24, 25). However, some of the
probiotic strains currently employed in the health food
industry may not possess desirable traits such as being of
human origin, resistance to technological processes (i.e.
viability and activity in delivery vehicles), resistance to
gastric acidity and bile toxicity, capacity to adhere to gut
epithelial tissue, ability to colonise the host GIT, and
production of antimicrobial substances (26, 27).
This study describes the behaviour and effects, following
its administration to healthy adult humans, of L. salivarius
UCC118, a strain which was originally isolated from the
ileal–caecal region of the intestinal tract of a healthy
human adult (20, 21). Previously, speci c criteria were
employed to determine the suitability of the strain for use
as a probiotic. These included the ability of the strain to
survive in human gastric acid at pH 2.5 and growth at
physiological concentrations of human bile (0.03% v:v)
(20, 21). Strain UCC118, originally isolated as crypt-ad-
hering bacteria, was also previously con rmed to be
strongly adhesive to the human adenocarcinoma cell lines
Caco-2 and HT-29 (20, 21).
The human gastrointestinal environment is a complex,
interactive system involving the host itself, ingested dietary
components, and many microbial species. Measurement of
ingested probiotic micro-organisms from faecal material is
problematic if the administered bacterial strains do not
possess speci c characteristics that facilitate their differen-
tiation from indigenous, closely related, strains (28). For
the purposes of this study, a previously selected rifampicin-
resistant derivative of L. salivarius UCC118 (22) was used
in order to facilitate enumeration of the strain from faecal
samples, and as a de ned method of distinguishing the
administered strain from indigenous lactobacilli.
Both fresh and fermented milk were effective as vehicles
in terms of delivery of the probiotic, as measured by
isolated faecal numbers, although fresh milk was mar-
ginally better than fermented product. A possible reason
for this may be more rapid gastric emptying for milk than
fermented product (29), with less exposure to gastric acid
and enzymes. In contrast, consumption of fermented milk
containing the L. salivarius UCC118Rif strain was associ-
ated with signi cant increases in faecal excretion of entero-
cocci and enhanced faecal numbers of total lactobacilli not
accounted for by consumption of the UCC118Rif Lacto -
bacillus alone. These changes were not as evident when the
probiotic bacteria were consumed in fresh milk and did
not occur in either of the control groups. It is likely that
the fermentative process undertaken by UCC118Rif lacto-
bacilli generates metabolic bio-active products that stimu-
late speci c microbial populations. Indeed, some of the
health bene ts of consumption of certain lactobacilli are
week 3 or 6 for any of the cytokines measured, including
IL-1a, IL-1b, IL-4, soluble IL-2 receptor, soluble IL-6
receptor, TNF-a, and IFN-g (p\0.05 in all cases).
The group that consumed the UCC118Rif strain in a
fermented milk vehicle but not those who consumed it in a
fresh milk vehicle exhibited a signi cant increase in granu-
locyte phagocytic activity (Table II). However, a similar
shift of phagocytic activity in the monocyte subpopulation
was not evident for any of the test subjects (data not
shown).
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Fig. 4. Faecal excretion of total lactobacilli associated with consumption of L. salivarius UCC118Rif. Total lactobacilli numbers isolated
from faeces (CFU:g wet weight) before (T0), immediately after (T1) and 21 days after (T2) consumption of Lactobacillus UCC118Rif-con-
taining fermented milk (*¾Statistically signi cant difference; pB0.05; means9SD).
Fig. 5. The effect of L. salivarius UCC118Rif consumption on faecal excretion of enterococci. Enterococci numbers isolated from faeces
(CFU :g wet weight) before (T0), immediately after (T1) and 21 days after (T2) consumption of UCC118Rif-containing fermented milk
(*¾Statistically signi cant difference; pB0.05).
Table I
Changes in salivary IgA reactivea against L. salivarius UCC118Rif associated with consumption of fermented milk -borne and fresh
milk-borne probiotic
Initiation of probioticProducts administeredb Day 21 of probiotic
consumptionconsumption
9.11 (14.62)3.42 (2.70)cFermented milk-borne UCC118Rif (n¾20)
3.05 (3.12)Probiotic-free fermented milk (n¾20) 4.02 (4.89)
3.92 (6.67)3.12 (6.51)Fresh milk-borne UCC118Rif (n¾20)
3.57 (3.52) 5.03 (6.82)Probiotic-free fresh milk (n¾20)
a Mean levels of salivary IgA antibody concentration (g:l).
b UCC118Rif was administered at a concentration of 1½108 CFU :ml fermented or fresh milk.
c Standard deviations are given in parentheses.
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Table II
Changes in peripheral granulocyte phagocytic activity a associated with consumption of fermented milk-borne and fresh milk-borne L.
salivarius UCC118Rif
Products administeredb Day 21 of probioticInitiation of probiotic
consumption consumption
76.37 (7.68)dFermented milk-borne UCC118Rif (n¾20) 70.05 (9.51)c
Probiotic-free fermented milk (n¾20) 72.50 (8.38) 69.56 (8.45)d
71.06 (11.02)Fresh milk-borne UCC118Rif (n¾20) 68.75 (8.55)
70.05 (10.18)64.84 (17.13)Probiotic-free fresh milk (n¾20)
a Phagocytic activity is expressed as a percentage of cells with ingested  uorescent bacteria, as determined by  ow cytometry.
b UCC118Rif was administered at a concentration of 1½108 CFU :ml fermented or fresh milk.
c Standard deviations are given in parentheses.
d There was a statistically signi cant difference in the change from baseline phagocytic activity for those subjects who received fermented
milk-borne UCC118Rif versus probiotic-free fermented milk for the 21 day period (p¾0.0088).
thought to be indirect and due to stimulation of the
bi dobacteria population and inhibition of anaerobes, al-
though in this study signi cant bi dogenic activity was not
observed in vivo with L. salivarius UCC118 Rif.
There has been unresolved speculation as to whether the
health bene ts associated with probiotic consumption are
dependent on the micro-organism becoming a long-term
resident in the gut. Few feeding studies in humans have
demonstrated persistent long-term colonisation by probi-
otic lactic acid bacteria (LAB) (30). In this study, we found
that  ve of the 40 subjects (12.5%) consuming L. salivarius
UCC118Rif displayed signi cant faecal concentrations of
the strain up to 3 weeks after feeding was discontinued and
one individual was excreting the probiotic strain 6 months
later. This was not correlated with local IgA responses and
colonisation was not an absolute requirement for probi-
otic-associated alterations in faecal  ora. Although opti-
mal dose and duration of consumption have not been well
correlated with impact on enteric  ora for any probiotic
(31) continual feeding will probably be required for most
individuals if probiotics in their current form are to be
exploited for health bene ts. This should not be taken to
imply that the probiotic is in simple transit within the
lumen of the digestive tract without any direct engagement
with the host.
Several lines of evidence in vivo and in vitro indicate that
probiotics engage and interact with host immune and
other mucosal cells (12, 32, 33). In this study, consumption
of L. salivarius UCC118Rif was associated with a speci c
secretary IgA anti-UCC118Rif response as detected in saliva
by a dilution-controlled, protein-standardised  ow cyto-
metric detection system. In contrast, a systemic serologic
immune response against the strain was not evident. Al-
though increased granulocyte (but not monocyte) phago-
cytic activity was observed in subjects fed the UCC118Rif
strain in fermented but not in fresh milk, and a similar
 nding has previously been reported after consumption of
L. acidophilus (34, 35), the biological signi cance of this is
unclear. It does, however, indicate an increased immune
status, which is a concept frequently, associated with, and
promoted by, the marketing of probiotics.
Modi cation of the host- ora interface with probiotics
promises much. Gastrointestinal disorders where probiotics
might be anticipated to have a therapeutic application
include antibiotic-associated diarrhoea; bacterial over-
growth and other diarrhoeal syndromes; in ammatory
bowel disease, and colonic cancer (1, 12, 36). Probiotics
also offer the very real potential to deliver therapeutically
relevant proteins including enzymes, vaccines and cytokines
(37). However, the scienti c credibility of the functional
food and probiotic industry suffers from an excess of soft
claims, anecdotal reports, and insuf cient data on probiotic
performance or mechanisms of action. It seems reasonable
to propose that putative probiotic strains be subjected to
rigorous study with current molecular technology in the
context of enteric microbial ecology, cellular physiology
and human immunology before launching expensive human
clinical trials in speci c diseases.
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